Petition Requests Pre-Market Approval For Supplement Weight-Loss Claims
This article was originally published in The Tan Sheet
Executive Summary
Manufacturers would need pre-market approval to make weight-loss claims for supplements if FDA implements a rulemaking recommended by petitioners, including GlaxoSmithKline, the manufacturer of OTC weight-loss drug alli.
You may also be interested in...
Glaxo’s Weight-Loss Petition Relied On “Deeply Flawed” Survey – AHPA
The American Herbal Products Association says GlaxoSmithKline used data from a flawed consumer survey when the firm asked FDA to reclassify weight loss claims as disease claims
CRN Says GSK Swings Wide Against Alli Competition With Weight-Loss Petition
The Council for Responsible Nutrition says GlaxoSmithKline's request that FDA reclassify weight-loss claims as disease claims would essentially eliminate nonprescription competition for GSK's OTC drug alli and "cripple the dietary supplement category.
Supplement Experts Expect Biggest Growth In Cognitive, Eye, Joint Categories
Consumers who want healthy minds in addition to healthy bodies are demanding supplements that boost and maintain cognitive acuity - driving the growth of a relatively new and potentially lucrative market